MEK Inhibitor
Trametinib with/without Radiation for Brain Metastasis
This trial is testing the effects of a drug called trametinib, with or without radiation therapy, in patients with brain metastases. Trametinib may stop the growth of tumor cells by blocking enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving trametinib with radiation therapy may be a better treatment for brain metastases.
Popular Filters
Trials for Diffuse Intrinsic Pontine Glioma Patients
Chemotherapy
PF-07799544 for Cancer
This trial tests a new cancer medicine, PF-07799544, taken regularly as a tablet. It is for people with advanced solid tumors who haven't responded to other treatments. The medicine may be used alone or with other drugs to improve its effectiveness.
CDK4/6 Inhibitor
Abemaciclib + Elacestrant for Brain Metastasis from Breast Cancer
This trial tests a combination of two drugs, elacestrant and abemaciclib, in patients with a specific type of breast cancer. It aims to find the best dose and see how well it works for those whose cancer has spread to the brain. The drugs work by blocking signals that help cancer cells grow and divide. Abemaciclib is a drug that has been approved for the treatment of certain advanced breast cancers.
Trials for Pituitary Adenomas Patients
Chemotherapy
PF-07799544 for Cancer
This trial tests a new cancer medicine, PF-07799544, taken regularly as a tablet. It is for people with advanced solid tumors who haven't responded to other treatments. The medicine may be used alone or with other drugs to improve its effectiveness.
CDK4/6 Inhibitor
Abemaciclib + Elacestrant for Brain Metastasis from Breast Cancer
This trial tests a combination of two drugs, elacestrant and abemaciclib, in patients with a specific type of breast cancer. It aims to find the best dose and see how well it works for those whose cancer has spread to the brain. The drugs work by blocking signals that help cancer cells grow and divide. Abemaciclib is a drug that has been approved for the treatment of certain advanced breast cancers.
Trials for HER2 Positive Patients
Monoclonal Antibodies
Tucatinib Combination for Breast Cancer
This trialis to test a new drug for advanced HER2+ breast cancer patients with brain metastases. Patients will get local therapy followed by the new drug and continue current care until disease progression or side effects.
Tyrosine Kinase Inhibitor
Neratinib + Capecitabine for Breast Cancer
This trial is testing a combination of neratinib and capecitabine for breast cancer patients with brain metastases. These patients' tumors did not show HER2 activity with usual tests but did with a special test, suggesting they might benefit from this treatment. Neratinib blocks growth proteins in cancer cells, while capecitabine kills them. Neratinib is approved for use in combination with capecitabine for advanced HER2-positive breast cancer.
MRI Screening for Brain Metastases in Breast Cancer
This trial aims to study how often patients with advanced types of breast cancer have undetected brain metastases. Participants will undergo brain imaging and provide a blood sample for analysis. They will also fill out
Phase 3 Trials
Radiation Therapy
Radiosurgery vs Whole Brain Radiation for Brain Metastasis
This trial compares two radiation treatments for brain tumors from non-melanoma cancers. One treatment is a focused, high-dose method, while the other treats the entire brain over several sessions. The goal is to determine which method controls tumors better and has fewer side effects on thinking and memory. The focused, high-dose method has been increasingly used over the past years as an effective treatment for brain metastases, often replacing the whole brain treatment due to its ability to improve outcomes and reduce side effects.
Radiation
Stereotactic Radiosurgery vs. HA-WBRT + Memantine for Brain Cancer
This trial is testing whether memantine used in combination with HA-WBRT helps to improve mental function (measured by how well patients can remember things) compared to those who receive HA-WBRT alone.
Trials With No Placebo
IRAK-4 Inhibitor
CA-4948 + Pembrolizumab for Melanoma
This trial will study the potential benefits of combining a novel oral medicine with aPD1 therapy for treating melanoma brain metastases, potentially reducing the need for radiation and improving patients' quality of life.
Chemotherapy
PF-07799544 for Cancer
This trial tests a new cancer medicine, PF-07799544, taken regularly as a tablet. It is for people with advanced solid tumors who haven't responded to other treatments. The medicine may be used alone or with other drugs to improve its effectiveness.
View More Related Trials
Frequently Asked Questions
Introduction to brain metastases
What are the top hospitals conducting brain metastases research?
When it comes to pioneering clinical trials for patients with brain metastases, several prominent hospitals are leading the charge. In Houston, M D Anderson Cancer Center stands out with an impressive 13 ongoing trials focused specifically on this condition and a total of 43 completed studies since their first brain metastases trial in 2004. Not far behind, Moffitt Cancer Center in Tampa is making significant strides as well, currently conducting nine active trials and having recorded a commendable history of 22 previous brain metastases studies since their initial trial in 2004.
In Urbana, Carle Cancer Center is contributing to advancements in this field with six ongoing clinical trials for brain metastases and a notable record of 14 previously conducted studies dating back to their inaugural trial in 2003. Meanwhile, at Dana-Farber Cancer Institute located in Boston, researchers are working diligently on six active clinical investigations while boasting a remarkable tally of 31 completed brain metastases trials since initiating their first study back in 2002.
Moreover adding itself among these esteemed institutions is the Ohio State University Comprehensive Cancer Center based out of Columbus. Although relatively new compared to its counterparts, they have already made substantial contributions by carrying out six currently active brain metastases trials along with eleven previously held investigations; theirs can be traced back only ten years ago to2012.
These leading hospitals across different locations demonstrate the commitment and progress being made within the medical community towards understanding and treating brain metastases. Each trial serves as an opportunity to expand our knowledge and improve patient outcomes for those facing this challenging condition. With continued research efforts at these institutions and others like them around the world, we move closer towards finding effective treatments that may ultimately transform lives affected by brain metastases
Which are the best cities for brain metastases clinical trials?
When it comes to brain metastases clinical trials, several cities emerge as prominent hubs of research and innovation. Boston, Massachusetts leads the way with 29 ongoing trials focusing on treatments like PF-07284890, Dose Escalation Cohorts - Monotherapy, Stereotactic Radiation, among others. New york, New York closely follows with 23 active studies exploring options such as PF-07284890 and Pembrolizumab combined with SRS. Houston, Texas also showcases its dedication to advancing brain metastases treatment through its 23 active trials investigating approaches like Stereotactic Radiosurgery and NovoTTF-200M device for Glioblastoma multiforme. While Tampa, Florida presents a range of clinical trials including Encorafenib and Phase 1b Substudy A Dose Expansion Cohort 2.
From coast to coast these cities provide patients dealing with brain metastases an opportunity to participate in cutting-edge clinical trials that could potentially revolutionize treatment options for this challenging condition.
Which are the top treatments for brain metastases being explored in clinical trials?
Clinical trials are paving the way for advanced treatments targeting brain metastases. Stereotactic radiosurgery, a precise radiation treatment technique, stands at the forefront with 10 ongoing trials and an impressive track record of 37 all-time clinical studies since its debut in 2004. Nivolumab, an immunotherapy drug, follows closely behind with five active trials and a solid foundation of 19 previous brain metastases trials starting from 2014. Additionally, stereotactic radiation and osimertinib show promise in their respective fields as they undergo testing in two active trials each while accumulating three and eight total brain metastases trials respectively as of now. The relentless pursuit to improve outcomes for patients battling this challenging condition remains steadfast through these groundbreaking investigations.
What are the most recent clinical trials for brain metastases?
Recent clinical trials offer hope for patients with brain metastases, a challenging condition that arises when cancer cells spread to the brain from other parts of the body. One promising treatment being studied is cemiplimab, which is currently in Phase 2 and has shown potential in targeting brain metastases. Another trial explores the combination of azeliragon and stereotactic radiosurgery (SRS) as a possible treatment option for this complex condition. Additionally, a single-arm study aims to evaluate the efficacy of a specific treatment approach for brain metastases. These ongoing trials present opportunities to improve outcomes and enhance the quality of life for individuals facing this difficult diagnosis.
What brain metastases clinical trials were recently completed?
Recent clinical trials have made significant progress in the field of brain metastases, offering hope for patients facing this challenging condition. In October 2020, Blue Earth Diagnostics completed a trial investigating the potential of 18F fluciclovine. Not far behind, in August 2020, they concluded another trial with the same therapy. Emory University also achieved an important milestone by completing their WP1066 study in May 2020. These recent advancements signify the commitment of researchers to find effective treatments for brain metastases and bring us closer to improved outcomes for patients dealing with this complex disease.